Latest Hotspot

AstraZeneca's C5 complement inhibitor, Eculizumab, has been approved in China for a new indication: the treatment of Neuromyelitis Optica Spectrum Disorder

23 October 2023
3 min read

Recently, AstraZeneca announced that the National Medical Products Administration (NMPA) of China has approved C5 complement inhibitor Eculizumab for the treatment of adults with anti-aquaporin-4 (AQP4) antibody-positive neuromyelitis optica spectrum disorder (NMOSD).

👇Please click on the image below to directly access the latest data (R&D Status | Core Patent | Clinical Trial | Approval status in Global countries) of this drug.

Eculizumab is a recombinant monoclonal antibody that can recognize and bind to antigens present in the human body. It attaches to the C5 complement protein and blocks it. The C5 complement protein is a part of the immune system's complement cascade reaction, and its activation can lead to the aforementioned condition. Soliris (eculizumab, or Eculizumab) is a drug used for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), generalized myasthenia gravis (gMG) and NMOSD. Eculizumab was originally developed by Alexion, and on December 12, 2020, AstraZeneca acquired it and another long-acting C5 complement inhibitor Ultomiris (Ravulizumab) when it purchased Alexion for $39 billion. According to AstraZeneca's financial report, the global sales of Eculizumab reached $3.762 billion in 2022.

The approval of Eculizumab in China for NMOSD is mainly based on the results of a pivotal phase 3 PREVENT study. The study showed that Eculizumab treatment significantly reduced relapse risk, with statistical and clinical significance. At week 48, 98% of patients treated with Eculizumab (compared to 63% of placebo-treated patients) had no relapses (a relative risk reduction of 94.2%), and this benefit persisted up to week 144. Additionally, in the 144-week PREVENT study, 96% of patients treated with Eculizumab had no relapses, while the no relapse rate was only 45% in placebo-treated patients. The safety and tolerability of Eculizumab were consistent with the results during the PREVENT study and its open-label extension studies. The most common adverse reactions during treatment were upper respiratory tract infection, headache, nasopharyngitis and nausea.

👇Please click on the picture link below for free registration or login directly if you have freemium accounts, you can browse the latest research progress on drugs, indications, organizations, clinical trials, clinical results, and drug patents related to this target.

图形用户界面, 应用程序

描述已自动生成

According to the Synapse database, as of October 20, 2023, there are 45 drugs under development targeting C5, with 77 indications, 70 research institutions involved, 371 related clinical trials, and as many as 193,768 patents. We look forward to the continued performance of Eculizumab.

图形用户界面, 文本, 应用程序

描述已自动生成

Advances in Clinical Research on Amylase Inhibitor
Advances in Clinical Research on Amylase Inhibitor
23 October 2023
Amylase is an essential enzyme found in the human body that plays a crucial role in the digestion of carbohydrates.
Read →
UCB's innovative therapy, IL-17A/F inhibitor bimekizumab, has been approved by the FDA for the treatment of plaque psoriasis
Latest Hotspot
3 min read
UCB's innovative therapy, IL-17A/F inhibitor bimekizumab, has been approved by the FDA for the treatment of plaque psoriasis
23 October 2023
Recently, UCB announced that the FDA has approved Bimzelx(bimekizumab) for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic treatment or phototherapy.
Read →
Analysis on the Clinical Research Progress of β-lactamase inhibitor
Analysis on the Clinical Research Progress of β-lactamase inhibitor
22 October 2023
β-lactamase is an enzyme found in the human body that plays a crucial role in the defense against bacterial infections.
Read →
Pharmaceutical Insights: tegafur's R&D Progress and its Mechanism of Action on Drug Target
Drug Insights
4 min read
Pharmaceutical Insights: tegafur's R&D Progress and its Mechanism of Action on Drug Target
26 October 2023
This article summarized the latest R&D progress of tegafur, the Mechanism of Action for tegafur, and the drug target R&D trends for tegafur.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.